RGEN
$113.88-3.73 (-3.17%)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Recent News
Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin
Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CE
Repligen Earnings Beat Puts Focus On Analytics Growth And Rich Valuation
Repligen (NasdaqGS:RGEN) reported earnings in which revenue exceeded company guidance. Operating income also came in ahead of the guidance range, supported by organic growth. Management highlighted strong performance in the Analytics and Proteins segments as key drivers. Repligen focuses on bioprocessing technologies that support biologic drug production, an area that continues to attract investment as complex therapies remain a priority for many pharma and biotech companies. The latest...
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.
2 Growth Stocks Set to Flourish and 1 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.